Analysts said the second batch of the gem purchase "cheap"

Core tip: This group of companies with high gross profit margin, good growth, price and P/E ratio is lower, overall cost-effective than the first batch and the third batch of the start-up board company, it is "inexpensive." Every reporter Shaoyan today, the second batch of Gem 9 companies began online purchase. Compared with the first and third batch of enterprise Board companies, the second batch of 9 companies are more favored by the major brokerage analysts, many analysts to the "Daily economic news" Reporter said that the company's high gross profit margin, growth, price and P/E ratio is lower, the overall cost-effective than the first and third batch of the launch of the Enterprise Board Company, it is " Cheap ".　　And a lot of money or choice in Monday and Thursday purchase, so this batch of gem will also be relatively higher. The second batch of 9 companies to raise a total of 4.271 billion yuan, if investors want all shelf purchase, it will need 2.78 million funds.　　To this end, the daily economic news reporter in a comprehensive number of dozen new experts on the basis of recommendations, specially for the reader configured five purchase packages, to help everyone reasonable and efficient use of new funds to obtain maximum benefits. 9 companies to raise more than 2.45 billion yuan in the second batch of 9 companies originally proposed to collect capital of 1.821 billion yuan, the actual raise capital of 4.271 billion yuan, over raising capital of 2.45 billion yuan, the proportion of the super raised to 134.54%.　　One of the largest financing of the love of ophthalmology, to raise the amount of funds for 340 million yuan, and the actual fund-raising for 938 million yuan, over 598 million yuan, the proportion of super raise to 175.9%, followed by the net-bed technology, to raise capital of 242 million yuan, the actual raise capital of 552 million yuan, the proportion of the increase is From the industry characteristics, the 9 gem companies involved in the Internet, medical services, technical testing, high-end logistics, pharmaceutical industry, the industry is widely distributed.　　Among them, the core business of 6 companies are based on high technology, respectively, Ding Han technology, China testing, billion-Wei Li, network technology, China Yuan Electric and silicon bao technology. Industry analysts are pretty bullish on the second batch of gem companies. Wanguo analyst Lin Jin, in an interview with the Daily economic news, said the second batch of companies ' overall quality was better than that of the gem company, which was issued in Thursday. Among the 9 new shares, many enterprises are leading the respective market segments and benefiting from the sustainable development of downstream industries.　　Compared with the first batch of gem companies, the second group of 9 companies, the level of gross profit is also relatively high, 2008 average of 51%, slightly higher than the first batch of 48%. Citic Securities analyst Tangkuang also pointed out: "Overall, the second batch of 9 gem new stock overall quality is better, the market is expected in the next three years net profit annual composite growth rate of up to 33.3%." "And the 9 companies also show a certain advantage in the price of the issue. Century Securities analyst Lu Lihua pointed out that most of the 9 companies, the majority of the company's price is lower than the number of quotations, the highest prices for Ding Han technology 37 yuan/share, the lowest for xinning logistics 15.6 yuan/share. At the same time, the issue of the IPO isLower than the first batch of gem companies, of which the highest price-earnings ratio is the net-bed technology, 63.16 times times, the lowest for xinning logistics, up to 45.48 times times.　　Two companies or into the application of star because of the overall quality of 9 enterprises, different analysts preferred to recommend the stock is not exactly the same, but the AI er and lithium billion can appear in most of the list of analysts, the IPO is the Star enterprise. Lin Jin said: "From the agency's enthusiasm to participate in the inquiry, the agency to participate in the most inquiry is the love of ophthalmology, followed by billion-Li and net-bed technology." "Lin Jin the most of the purchase of enterprises, including Love Eye, Ding Han technology, billion-Wei Li and network technology.　　Citic Securities analyst Tangkuang's list includes Ding Han technology, Yili Li, ai er and Zhong Yuan Huadian, while the century Securities analyst Lu Lihua is the top billion Li, Ai er and North land pharmaceutical industry. In addition, these 9 companies are also bright spots. From the Business Innovation model, xinning Logistics in the industry to explore and form a VMI and DC innovation business model; in combination with the national conditions of China's medical system reform, the creative establishment of the "three-level chain" business model. In addition, there are some other points in this batch of new shares.　　Such as Ai ER is the first private medical institutions to land in the domestic capital market; North Land pharmaceutical industry is the first from the "New Sanbanxi" to the gem of the listing of pharmaceutical companies; silicon technology stock rights are more dispersed, no actual control people; Ding Han technology has a higher technology, capital and market access barriers; 5 Big Purchase Package options as the number of these 9 gem companies and the distribution price difference is not too large, analysts expect the difference may not be too big.　　Lin Jin is expected to participate in the purchase of funds may be in 400 billion yuan ~6000 billion.　　For the ranking of the stock check rate, analysts generally believe that the Chinese Yuan Huadian, Ai Seoul, the high probability of eye, and sunning logistics and the North land pharmaceutical industry's low rate.　　Lin Jin that, the likelihood of the highest probability of the eye, for 0.8%~1.5%, second in turn for the CLP, China testing, network technology, Ding Han technology, billion-Wei Li, North Land medicine; Silicon Bao technology and xinning Logistics can be low, probably in the 0.33%~0.6%.　　Dollars, an analyst at Datong Securities, China-yuan Chinese electricity may be the highest, in the 0.77%~0.96% between the two, followed by Ding-han technology, ai er, silicon bao technology, China testing, network technology, lithium billion Li, the North land pharmaceutical and xinning Logistics, the lowest rate in 0.37%~0.48%. Analysts said, because the overall size is relatively small, the single stock of the purchase limit is relatively low, on the individual shares of the purchase, the rate will not be too high, mainly to see luck.　　According to a number of analysts, the daily economic news reporter for different funds for investors configured five major purchase packages. 100,000 below: Because the probability of less money is very low, you can choose the fundamentals of Better network technology, love ophthalmology, lithium billion li;The lowest price of xinning logistics. 150,000 ~20 million: can be in the north of the pharmaceutical industry (shelf 178,600), xinning Logistics (shelf purchase 156,000), billion-Wei Li (shelf purchase 180,000), in any one of the selected shelf for the purchase.　　Although these three new shares are relatively low, but may be a small number of subscriptions, but there are unexpected gains. 200,000 ~50 million: The first option is to choose the Net-bed technology (shelf requisition need 360,000) or Ding Han technology (shelf requisition 370,000) for shelf purchase, at the same time with the billion-latitude lithium can (shelf purchase need 180,000).　　The second option is all the funds to choose shelf Ophthalmic (700,000), the main value of its higher rate and better fundamentals.　　500,000 ~100 million: can be shelf for the purchase of love ophthalmology (shelf requisitions need 700,000), at the same time in the network of Technology (shelf purchase 360,000), Ding Han technology (shelf to purchase 370,000) and silicon technology (shelf requisition 230,000) in the three selected one. 1 million ~300 million: shelf after the purchase of ophthalmology, and then in accordance with the network of Technology, CLP, China testing, Ding Han technology in the order of choice, shelf purchase after a second consideration, when all can not shelf purchase, as far as possible to obtain the number of the most varieties.